TPSTHealthcare · BiotechnologyTPST Stock Forecast: Tempest Therapeutics, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Tempest Therapeutics, Inc. hold a median 12-month price target of $11 — +1184.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
TPST stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Tempest Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Momentum (6): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Tempest Therapeutics, Inc. — and when they’d sell — is the membership.
TPST stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TPST, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +1184.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Jan 2026 | HC Wainwright & Co. | Upgrade | Buy | $11 |
| 22 Jan 2026 | HC Wainwright & Co. | Upgrade | Buy | — |
| 10 Apr 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 10 Apr 2025 | Scotiabank | Downgrade | Sector Perform | — |
| 28 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Mar 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 13 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2024 | Piper Sandler | Maintains | Overweight | — |
| 10 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 June 2024 | Piper Sandler | Reiterates | Overweight | — |
| 20 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Mar 2024 | Scotiabank | Initiates | Sector Outperform | — |
| 13 Mar 2024 | Scotiabank | Initiates | Sector Outperform | — |
| 12 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Feb 2024 | Jefferies | Initiates | Buy | — |
| 11 Oct 2023 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TPST analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Tempest Therapeutics, Inc. (TPST) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.1×
- Price / sales
- —
- Price / book
- 15.4×
- EV / EBITDA
- −0.9×
Cheaper than 77% of US stocks
Cheaper than 7% of US stocks
Cheaper than 67% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −721.0%
- Return on assets
- −61.7%
- Dividend yield
- —
Higher than 2% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
TPST vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TPST appears on the weeks it earns a place.
Frequently asked questions about TPST stock
What is the TPST stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Tempest Therapeutics, Inc. have a median 12-month price target of $11, with estimates ranging from $11 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TPST stock a buy right now?
Of the 1 analysts covering Tempest Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tempest Therapeutics, Inc. 34 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TPST?
As at 1 Aug 2026, Tempest Therapeutics, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
Will TPST stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +1184.6% from the last close, and Ticker Nerd's factor model ranks Tempest Therapeutics, Inc. 34 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TPST stock forecast for 2030?
No analyst covering Tempest Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TPST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $11 over the next 12 months.
What does Tempest Therapeutics, Inc. do?
Tempest Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies designed to exploit the immune system for cancer treatment.
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies designed to exploit the immune system for cancer treatment. Its primary function is the advancement of oncology programs centered on modulating key immune response pathways that are often dysregulated in cancer. Tempest Therapeutics targets various indications in the immune-oncology landscape, with a pipeline that includes both proprietary small molecules and therapeutic combinations. The company's research and development efforts emphasize precision medicine and the potential to treat a broad spectrum of tumor types, thus impacting cancer treatment strategies significantly. Tempest Therapeutics operates in a highly specialized sector characterized by rapid scientific advancements and regulatory processes, playing a significant role in the biotech industry's pursuit of groundbreaking cancer therapies.
CEO Mr. Stephen R. Brady J.D., LLM · 5 employees · United States · https://www.tempesttx.com